Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
36.91
-0.61 (-1.63%)
At close: Oct 30, 2026, 4:00 PM EDT
37.00
+0.09 (0.24%)
After-hours: Oct 30, 2026, 7:53 PM EDT
Roivant Sciences Employees
Roivant Sciences had 721 employees as of March 31, 2026. The number of employees decreased by 29 or 3.87% compared to the previous year. That makes Roivant Sciences the 17,265th largest employer in the world and 2,394th in the United States.
Employees
721
Change (1Y)
-29
Growth (1Y)
-3.87%
Revenue / Employee
$10,447
Profits / Employee
-$369,283
Market Cap
26.66B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 721 | -29 | -3.87% |
| Mar 31, 2025 | 750 | -158 | -17.40% |
| Mar 31, 2024 | 908 | 4 | 0.44% |
| Mar 31, 2023 | 904 | 41 | 4.75% |
| Mar 31, 2022 | 863 | 198 | 29.77% |
| Jun 30, 2021 | 665 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Genmab | 3,119 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| Insmed | 1,664 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
ROIV News
- 4 days ago - Roivant Sciences price target raised to $56 from $46 at Citi - TheFly
- 10 days ago - Roivant Sciences price target raised to $62 from $55 at TD Cowen - TheFly
- 11 days ago - Roivant Sciences Transcript: Study result - Transcripts
- 11 days ago - Roivant Sciences Press release: Study result - Filings
- 11 days ago - Roivant Sciences Slides: Study result - Filings
- 11 days ago - Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) - GlobeNewsWire
- 11 days ago - Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 - GlobeNewsWire
- 19 days ago - Citi opens ‘upside 90-day catalyst watch’ on Roivant Sciences - TheFly